HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

Moleculin Biotech (MBRX) has received first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol ...

O n Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA vaccines in humans. The bill was sponsored by State Representative Greg Kmetz ...

Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...

A comprehensive strategy that combines pharmacological advances, vector control, public outreach to raise awareness and ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

In addition to her stewardship of TNX-102 SL, Siobhan has played key roles advancing our pipeline of small ... Sciences at Trinity College, Dublin, and is a European Union Qualified Person. Her ...

In addition to her stewardship of TNX-102 SL, Siobhan has played key roles advancing our pipeline of small ... Sciences at Trinity College, Dublin, and is a European Union Qualified Person. Her ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

The continued shift towards telemedicine and remote hyper-personalized care elevates the role of digital and communications technologies as key components ... EU’s European Medicines Agency ...

(RTTNews) - European stocks were flat to slightly higher on Thursday after China rolled out a basket of measures to funnel capital into the country's stock markets. Amid much uncertainty over the ...